The tariff threat targets a low-margin industry that supplies most US prescriptions, creating a localisation test that could raise costs before it rebuilds capacity.
President Donald Trump has said imported generic medicines will face a 100 percent US tariff from August 2028 and a 200 percent tariff a year later unless manufacturers shift production to the United States. Reuters reported that generics would remain tariff-free for two years before the rates apply. A follow-up Reuters report said Swiss generic-drug maker Sandoz plans to engage with US officials after the threat.
The policy is sector-specific but globally important. More than 90 percent of medicines dispensed in the United States are generics. They are cheap because companies run large international supply chains, use specialised production sites and operate on narrow margins. A 100 percent tariff would not be a small adjustment. A 200 percent tariff could force a restructuring of supply or make some imports commercially impossible.
EU Global has covered the broader EU-US tariff settlement and its suspension clause. Generic medicines add a sharper public-interest dimension. Tariffs on cars, steel or consumer goods raise prices. Tariffs on medicines can affect health systems, pharmacies and patients.
The two-year delay is designed to give companies time to localise. But pharmaceutical localisation is not simple. Plants require regulatory approval, quality validation, trained staff, supply of active pharmaceutical ingredients, environmental controls and repeated inspections. A company cannot move a complex product line as quickly as it can move a warehouse.
Sandoz illustrates the exposure. The company has limited US production and derives a meaningful share of sales from North America. Other European and Indian manufacturers face similar dilemmas: invest in US capacity, accept tariff risk, change product portfolios or negotiate exemptions.
The economics are difficult. Generics are not blockbuster branded drugs with high margins. If tariffs apply, companies may try to pass costs to wholesalers, pharmacies, insurers or government programmes. But reimbursement systems may resist. Some products could become uneconomic, leading to shortages rather than higher-priced supply.
That is the central policy risk. Localisation can improve resilience if it produces real domestic manufacturing capacity. It can also reduce resilience if tariffs discourage imports before US capacity exists. A medicine shortage caused by trade policy would be politically damaging and medically dangerous.
The plan also exposes the difference between strategic medicines policy and tariff politics. Governments have good reasons to reduce dependence on fragile supply chains for essential drugs, antibiotics, injectables and active ingredients. But a blanket tariff tool may not distinguish between products where domestic production is feasible and products where international specialisation keeps prices low.
Europe will watch closely because European companies serve the US market and because similar localisation arguments could appear in reverse. If the United States uses market access to force pharmaceutical production onshore, Brussels may face pressure to secure its own medicines supply through procurement, stockpiles or industrial incentives.
The supply-chain geography extends beyond Europe. Many active pharmaceutical ingredients and intermediates are produced in India and China. A US tariff on finished generics may not solve dependence if US-based plants still rely on imported inputs. True resilience requires mapping the chain from raw chemicals to packaging, not only moving final assembly.
The Trump administration may argue that the deadline is long enough to trigger investment without immediate price increases. Industry will argue that certainty is needed before committing capital, and that tariffs are a blunt tool for products with public-health importance. Both sides will use the next two years to bargain.
For patients, the concern is simple: will medicines remain available and affordable? Trade policy often treats supply chains as abstract. Generic medicines make them personal. The same low-cost global system that politicians criticise is the system that keeps millions of prescriptions cheap.
The tariff plan therefore creates a hard test. If it produces targeted, reliable US capacity without shortages, it will be presented as industrial-policy success. If it raises costs, forces withdrawals or disrupts supplies, it will show the danger of using punitive tariffs to reshape a low-margin health sector. European manufacturers should prepare for both outcomes.
The next two years will be a negotiation period disguised as a grace period. Companies will lobby for exemptions, transition rules and product categories that recognise medical necessity. Hospitals, insurers and pharmacy groups will warn against supply disruption. The administration will use the tariff deadline to demand investment announcements. The result may be a patchwork of reshoring commitments and carve-outs rather than a clean relocation of the industry.
